Related Experiment Video
Updated: Jun 15, 2025
06:45
Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
Published on: June 2, 2023
2.1K
Ensifentrine: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|August 28, 2024
Summary
Ensifentrine, a new inhaled therapy, is now approved for chronic obstructive pulmonary disease (COPD) maintenance treatment in adults. This selective phosphodiesterase inhibitor marks a significant advancement in respiratory disease management.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Drug Development
Background:
- Ensifentrine is an inhaled, selective phosphodiesterase (PDE) 3 and PDE4 inhibitor.
- It is being developed for various respiratory diseases, notably chronic obstructive pulmonary disease (COPD).
Purpose of the Study:
- To summarize the key development milestones of ensifentrine.
- To highlight the path to its first regulatory approval for COPD maintenance treatment.
Main Methods:
- Review of preclinical and clinical development data.
- Analysis of regulatory submission and approval processes.
Main Results:
- Ensifentrine (OHTUVAYRE™) inhalation suspension received US FDA approval in June 2024.
- Approval is for the maintenance treatment of COPD in adult patients.
Conclusions:
- Ensifentrine represents a significant advancement in COPD treatment options.
- The development journey culminated in a crucial regulatory milestone for respiratory care.
Related Concept Videos
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
142
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142
01:12First Pass Effect
5.3K
Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
5.3K